Upstream Bio: The Reset Is The Opportunity, Initiating At Buy
Willow Tree Research has initiated a Buy rating on Upstream Bio, a small-cap biotech company. The company's lead asset, Verekitug, shows promise in treating severe asthma and CRSwNP, supported by strong phase 2 data. Upstream Bio is currently trading at an enterprise value of under $200 million, presenting a potential investment opportunity.
- ▪Willow Tree Research has initiated a Buy rating on Upstream Bio.
- ▪The lead asset, Verekitug, demonstrates competitive efficacy in severe asthma and CRSwNP.
- ▪Upstream Bio is trading at an enterprise value of under $200 million.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4910030-upstream-bio-the-reset-is-the-opportunity-initiating-upb-at-buy"},"author":{"@type":"Person","name":"Willow Tree…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
